Unless otherwise defined herein, the capitalised terms used in this announcement have the same meaning as those used in the Company's announcements released on 3 July 2024.

5 July 2024

Physiomics Plc

("Physiomics" or the "Company")

Result of WRAP Retail Offer

Physiomics plc, (AIM: PYC), is pleased to announce, further to the announcements on 3 July 2024, the completion of the WRAP Retail Offer, at the same issue price as the previously announced Placing (together, the "Fundraise"). The WRAP Retail Offer, which closed at 4:30 p.m. yesterday and which was oversubscribed, has raised gross proceeds of £25,000 through the issue of a total of 4,166,667 new Ordinary Shares to existing retail shareholders in the United Kingdom.

The Fundraise, which is conditional on Admission, raises gross proceeds of, in aggregate, £406,417, via the issue of 63,569,573 Placing Shares pursuant to the Placing and  4,166,667 WRAP Retail Offer Shares pursuant to the WRAP Retail Offer.

Use of Proceeds

In order to further develop its business and accelerate growth, the Company targeted a raise of £406,417  with the intention of using the net proceeds of the fundraise towards activities including:

·    Recruitment of a Head of Mathematical Modelling Service Line to accelerate conversion of the pipeline and drive operational excellence.

·    Further investment in Business Development and Marketing to build and strengthen the pipeline, expand into new therapeutic areas, develop its data science offering and launch its biostatistics offering.

·    Build a biostatistics capability, including team expansion, development of processes, acquisition of necessary tools and exploration of strategic options.

·    Implementation of the personalised dosing tool on the DoseMeRx Platform, enabling it to be available to clinicians across the US and deliver on a study in partnership with DoseMeRx to further develop the tools G-CSF functionality.

Admission and Total Voting Rights

Applications have been made for the Placing Shares and the WRAP Retail Offer Shares to be admitted to trading on AIM, which is expected to take effect and dealings to commence at 8:00 a.m. on or around 9 July 2024 ("Admission").

Following Admission, the Company will have 203,208,718 Ordinary Shares in issue. Since the Company currently holds no shares in treasury, the total number of voting rights in the Company will be 203,208,718.These figure may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information, please contact:

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

Winterflood Retail Access Platform

Joe Winkley & Sophia Bechev

+44 (0)20 8100 0000

Further information on the Company can be found on its website at www.physiomics.co.uk.

The Company's LEI is 213800A71DSZ6ABMTQ91.